Morningstar

Ferrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of Schedule

This is a randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetics of FNP-223 (oral formulation) in slowing the progression ...
Business Wire

Alzprotect Announces Supportive Results from Open-Label Extension of Phase 2a Study for Progressive Supranuclear Palsy (PSP)

LILLE, France--(BUSINESS WIRE)--Alzprotect, a French biopharmaceutical company, is pleased to announce the successful completion of the open-label extension (OLE) phase following the Phase 2a clinical ...

Axon Neuroscience's Immunotherapy Selected for Landmark Combination-Therapy Alzheimer’s Clinical Trial in U.S., Supported by $151 Million Grant

Axon Neuroscience’s active tau immunotherapy, AADvac1, has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Phase 2 Alzheimer’s disease clinical trial, while ...